Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

C.E. Quinn, P.K. Hamilton, C.J. Lockhart, Gary McVeigh

Research output: Contribution to journalArticlepeer-review

104 Citations (Scopus)


Thiazolidinediones (TZDs) have been used for the treatment of hyperglycaemia in type 2 diabetes for the past 10 years. They may delay the development of type 2 diabetes in individuals at high risk of developing the condition, and have been shown to have potentially beneficial effects on cardiovascular risk factors. TZDs act as agonists of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) primarily in adipose tissue. PPAR-gamma receptor activation by TZDs improves insulin sensitivity by promoting fatty acid uptake into adipose tissue, increasing production of adiponectin and reducing levels of inflammatory mediators such as tumour necrosis factor-alpha (TNF-alpha), plasminogen activator inhibitor-1(PAI-1) and interleukin-6 (IL-6). Clinically, TZDs have been shown to reduce measures of atherosclerosis such as carotid intima-media thickness (CIMT). However, in spite of beneficial effects on markers of cardiovascular risk, TZDs have not been definitively shown to reduce cardiovascular events in patients, and the safety of rosiglitazone in this respect has recently been called into question. Dual PPAR-alpha/gamma agonists may offer superior treatment of insulin resistance and cardioprotection, but their safety has not yet been assured
Original languageEnglish
Pages (from-to)636-645
Number of pages10
JournalBritish Journal of Pharmacology
Publication statusPublished - Feb 2008

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Thiazolidinediones: effects on insulin resistance and the cardiovascular system.'. Together they form a unique fingerprint.

Cite this